| Fifteen Years of Progress: Biopharmaceutical Industry Survey Results |
1 |
| Media Requirements for Different Cell Sources |
1 |
| Taking Therapeutic Antibodies to the Next Level |
1 |
| Real-Time Characterization of Biotherapeutics and Comparability of Biosimilars |
1 |
| Using TEM-Based Image Analysis to Validate the Presence of HA Spikes on Influenza VLPs |
1 |
| Achieving Process Balance with Perfusion Bioreactors |
1 |
| Changing Perceptions: An Understanding of Lyophilization Advancements |
1 |
| Challenges with Successful Commercialization of Biosimilars |
1 |
| What's New in Manufacturing: Process Chromatography |
0 |
| Applying GMPs in Stages of Development |
0 |
| Container Closures: Leaving Nothing to Chance |
0 |
| Driving Improved Access to Biosimilars |
0 |
| Streamlining Operations in Fill/Finish |
0 |
| Stability Indicating Methods for Aluminum Adsorbed Vaccine Products |
0 |
| Using Software in Process Validation |
0 |
| Best Practices for Selecting a Top-Quality Cell Line |
0 |
| What's New in Upstream Technologies |
0 |
| Formulating Biologic Drugs for Sterile Fill/Finish |
0 |
| The Link Between Data Integrity and Quality Culture |
0 |
| Contract Organizations Expanded in Autumn |
0 |
| Can QRM Transform Biopharmaceutical Operational and Quality Culture Excellence? |
0 |
| Overcoming Challenges in ADC Bioconjugation at Commercial Scale |
0 |
| Outsourcing Development: Small-Scale to Commercial |
0 |
| Predictability Improves Prospects for Biopharma Patent Holders |
0 |
| Where Automation Meets Skill Set |
0 |
| FDA Clarifies Worldwide Inspection Policies |
0 |
| A Plastic Pipeline for Commercial Bioprocessing? |
0 |
| Validating Virus Clearance in a Single-Use System Part 1: Film Adsorption and Virus Inactivation Studies |
0 |
| Using Nondestructive in-situ Measurements to Ensure Lyophilized Product Stability |
0 |
| Going Global in Biopharma Regulatory Affairs |
0 |
| Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic Drugs |
0 |
| Leveraging Computational Models of Glycosylation for Biopharma QA |
0 |
| Separation and Purification of a Tissue-Type Plasminogen Activator from Trichoderma reesei |
0 |
| What's New in Downstream Processing |
0 |
| Cleaning Chromatography Resin Residues from Surfaces |
0 |
| Reinventing the Biomanufacturing Wheel |
0 |
| Rising to the Challenge of Biologic Drug Formulation |
0 |
| Demonstrating Results with Antibody-Drug Conjugates |
0 |
| Science Focus Fuels Successful Process Development for Startups |
0 |
| The Evolving Role of Starting Materials in Cell and Gene Therapy |
0 |
| Antibody Purification Process Development and Manufacturing |
0 |
| Prevent, Detect, and Remove: Viral Control for Viral Vectors |
0 |
| Building a Biopharma Company |
0 |
| Quality Issues Offset Biomedical Advances |
0 |
| Meeting the Challenge of Patient-Centered Clinical Trials |
0 |
| Transcriptomics and the Production of Recombinant Therapeutics |
0 |
| Understanding Validation and Technical Transfer, Part 3 |
0 |
| Rapid Adventitious Agent Testing Remains a Real Need |
0 |
| Automation Trend in Fill/Finish Reduces Contamination Risk |
0 |
| Challenges in Cell Harvesting Prompt Enhancements |
0 |
